SS
ALNY icon

SBI Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

SBI Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53K Buy
176
+120
+214% +$36.2K ﹤0.01% 1139
2026
Q1 		$18.5K Sell
56
-91
-62% -$31K ﹤0.01% 1491
2025
Q4 		$58.5K Buy
147
+84
+133% +$37.2K ﹤0.01% 1029
2025
Q3 		$28.7K Hold
63
– – ﹤0.01% 1312
2025
Q2 		$20.5K Buy
63
+23
+58% +$6.36K ﹤0.01% 1401
2025
Q1 		$10.8K Buy
40
+4
+11% +$1.03K ﹤0.01% 1579
2024
Q4 		$8.47K Buy
+36
New +$9.47K ﹤0.01% 1710

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's ALNY Position: Q2 2026 in Review

SBI Securities increased its Alnylam Pharmaceuticals (ALNY) stake by 214% in Q2 2026, buying an estimated $36.2K and bringing the position to 176 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

SBI Securities first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $58.5K in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SBI Securities held 176 shares of Alnylam Pharmaceuticals worth $53K as of Q2 2026.
  • SBI Securities bought 120 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $36.2K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1139 holding.
  • SBI Securities first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Alnylam Pharmaceuticals position peaked at $58.5K in Q4 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.